Grail: Bob Ragusa, Hans Bishop
Illumina has appointed Bob Ragusa as CEO of its subsidiary Grail. He succeeds Hans Bishop, who will serve as adviser to the CEO through the end of 2021 and then step down.
Ragusa is Illumina’s chief operations officer, a role in which he helped scale the business globally. He was responsible for the company’s clinical lab services, supply chain, quality, life cycle management, information technology, global facilities, and real estate teams.
Prior to Illumina, he was executive VP of engineering and global operations at Accuray, a radiation oncology company, and senior VP of global operations at Applied Biosystems.
Ragusa holds a master’s degree in biomedical and electrical engineering from Carnegie Mellon University and an MBA from the University of Connecticut.
Bishop joined Grail’s board of directors in 2018 before becoming CEO. He founded Juno Therapeutics in 2013 and was the firm’s president and CEO until it was acquired by Celgene. He serves on the boards of Celgene and Agilent Technologies.
Foundation Medicine: Dymeka Harrison
Foundation Medicine has appointed Dymeka Harrison as chief commercial officer, where she will develop and execute global clinical commercial strategy and strengthen customer relationships, as well as establish new partnerships. She most recently served as VP of global strategic marketing at Abbott, overseeing global marketing efforts for the firm’s rapid diagnostics division. Harrison also worked at Qiagen as VP of sales for its QuantiFeron and AmniSure businesses and was a national sales manager in the clinical division at BioMérieux. She has also served as a sales director at Thermo Fisher Scientific.
Personalis: Robert Bruce
Personalis has appointed Robert Bruce to the newly created position of vice president of reimbursement. Bruce previously worked at Clinical Genomics, where he served as VP of reimbursement and interim CFO. Prior to Clinical Genomics he provided reimbursement and financial consulting services to a range of private and public companies, after serving in senior management roles with Enterix and Binax. He holds a B.A. in East Asian studies from Princeton University and an MBA from the School of Management at Yale University.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.